Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Gille

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|June 5, 2009
Differential inhibition of various adenylyl cyclase isoforms and soluble guanylyl cyclase by 2',3'-O-(2,4,6-trinitrophenyl)-substituted nucleoside 5'-triphosphatesSrividya Suryanarayana, Martin Göttle, Melanie Hübner, et al.
British Journal of Clinical Pharmacology|November 20, 2020
Pharmacometric analyses to characterize the effect of CSL112 on apolipoprotein A-I and cholesterol efflux capacity in acute myocardial infarction patientsBo Zheng, Danielle Duffy, Pierluigi Tricoci, et al.
Frontiers in Bioengineering and Biotechnology|June 13, 2025
Challenges in lentiviral vector production: retro-transduction of producer cell linesMaximilian Klimpel, Christin Obert, Monica Terrao, et al.
The Journal of Clinical Investigation|July 29, 2010
Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in miceJulien Hanson, Andreas Gille, Sabrina Zwykiel, et al.
Clinical Pharmacology in Drug Development|September 22, 2018
Pharmacokinetics and Safety of CSL112 (Apolipoprotein A-I [Human]) in Adults With Moderate Renal Impairment and Normal Renal FunctionMichael A Tortorici, Danielle Duffy, Rebecca Evans, et al.
The Journal of Clinical Investigation|December 3, 2005
GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushingZoltán Benyó, Andreas Gille, Jukka Kero, et al.
Biochemical Pharmacology|May 31, 2011
Structure-activity relationships for the interactions of 2'- and 3'-(O)-(N-methyl)anthraniloyl-substituted purine and pyrimidine nucleotides with mammalian adenylyl cyclasesCibele Pinto, Gerald H Lushington, Mark Richter, et al.
Molecular Pharmacology|April 19, 2011
Structural basis for the high-affinity inhibition of mammalian membranous adenylyl cyclase by 2',3'-o-(N-methylanthraniloyl)-inosine 5'-triphosphateMelanie Hübner, Anshuman Dixit, Tung-Chung Mou, et al.
Frontiers in Bioengineering and Biotechnology|September 22, 2025
Enhancing lentiviral production for WAS gene therapy: a comparative analysis of stable producer cell lines evaluating flatware system and adherent bioreactors in perfusion modeParameswari Singh, Nikki Indresh Lal, Monica Terrao, et al.
Molecular Pharmacology|December 6, 2008
Molecular analysis of the interaction of anthrax adenylyl cyclase toxin, edema factor, with 2'(3')-O-(N-(methyl)anthraniloyl)-substituted purine and pyrimidine nucleotidesHesham M Taha, Jennifer Schmidt, Martin Göttle, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
The Journal of Pharmacology and Experimental Therapeutics|June 5, 2009
Differential inhibition of various adenylyl cyclase isoforms and soluble guanylyl cyclase by 2',3'-O-(2,4,6-trinitrophenyl)-substituted nucleoside 5'-triphosphatesSrividya Suryanarayana, Martin Göttle, Melanie Hübner, et al.
British Journal of Clinical Pharmacology|November 20, 2020
Pharmacometric analyses to characterize the effect of CSL112 on apolipoprotein A-I and cholesterol efflux capacity in acute myocardial infarction patientsBo Zheng, Danielle Duffy, Pierluigi Tricoci, et al.
Frontiers in Bioengineering and Biotechnology|June 13, 2025
Challenges in lentiviral vector production: retro-transduction of producer cell linesMaximilian Klimpel, Christin Obert, Monica Terrao, et al.
The Journal of Clinical Investigation|July 29, 2010
Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in miceJulien Hanson, Andreas Gille, Sabrina Zwykiel, et al.
Clinical Pharmacology in Drug Development|September 22, 2018
Pharmacokinetics and Safety of CSL112 (Apolipoprotein A-I [Human]) in Adults With Moderate Renal Impairment and Normal Renal FunctionMichael A Tortorici, Danielle Duffy, Rebecca Evans, et al.
The Journal of Clinical Investigation|December 3, 2005
GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushingZoltán Benyó, Andreas Gille, Jukka Kero, et al.
Biochemical Pharmacology|May 31, 2011
Structure-activity relationships for the interactions of 2'- and 3'-(O)-(N-methyl)anthraniloyl-substituted purine and pyrimidine nucleotides with mammalian adenylyl cyclasesCibele Pinto, Gerald H Lushington, Mark Richter, et al.
Molecular Pharmacology|April 19, 2011
Structural basis for the high-affinity inhibition of mammalian membranous adenylyl cyclase by 2',3'-o-(N-methylanthraniloyl)-inosine 5'-triphosphateMelanie Hübner, Anshuman Dixit, Tung-Chung Mou, et al.
Frontiers in Bioengineering and Biotechnology|September 22, 2025
Enhancing lentiviral production for WAS gene therapy: a comparative analysis of stable producer cell lines evaluating flatware system and adherent bioreactors in perfusion modeParameswari Singh, Nikki Indresh Lal, Monica Terrao, et al.
Molecular Pharmacology|December 6, 2008
Molecular analysis of the interaction of anthrax adenylyl cyclase toxin, edema factor, with 2'(3')-O-(N-(methyl)anthraniloyl)-substituted purine and pyrimidine nucleotidesHesham M Taha, Jennifer Schmidt, Martin Göttle, et al.
Pageof 5